AbSci
The global leader in cutting-edge protein production technologies committed to reducing costs in the biopharmaceutical industry.
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | - | 20 % | (1 %) | (21 %) | 132 % | 170 % | 68 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (2086 %) | (1590 %) | (1296 %) | (1965 %) | (921 %) | (254 %) | (159 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (2111 %) | (1825 %) | (1934 %) | (2274 %) | (1025 %) | (349 %) | (202 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 932 % | 1025 % | 841 % | 1408 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
AbSci is a pioneering company in the biotech industry, focused on revolutionizing protein expression and biomanufacturing. The company operates in the biopharmaceutical market, serving clients that include pharmaceutical companies, biotech firms, and research institutions. AbSci's core innovation lies in its advanced protein expression platform, which features a semi-oxidizing cytoplasm and a dual inducible promoter system. These technologies allow for precise control over protein production rates, leading to higher quality and efficiency in drug manufacturing.
One of AbSci's standout offerings is SoluPure, a chromatography-free purification method that simplifies the downstream processing of proteins. This method removes bottlenecks typically associated with traditional purification techniques, making the production process faster and more cost-effective. AbSci's high-throughput workflow can generate cell lines that produce folded, active protein products in as little as three months, significantly reducing the time and resources needed for drug development.
AbSci's business model is built around providing cutting-edge biomanufacturing solutions that introduce efficiencies and cost savings to the biotech industry. The company makes money by partnering with pharmaceutical and biotech companies, offering them proprietary technologies and services that enhance their drug discovery and manufacturing processes. By doing so, AbSci aims to replace traditional mammalian expression platforms, such as CHO cells, with its more efficient and scalable solutions.
The company is supported by a group of experienced investors and is driven by a team of passionate, imaginative, and accomplished scientists. These professionals are dedicated to challenging established industry practices and creating extraordinary tools for drug discovery and manufacturing.
In summary, AbSci is a disruptive force in the biotech industry, offering innovative solutions that streamline protein production and purification, ultimately transforming how life-changing biologics are made.
Keywords: Biotech, Protein Expression, Biomanufacturing, Drug Discovery, SoluPure, Purification, High-Throughput, Cytoplasm, Promoter System, Biopharmaceutical.
